CDMO News and Research

RSS

SwiftScale Biologics: Cell-Free Synthesis of Biologics

In this interview, News-Medical talks to David Mace, CEO at SwiftScale Biologics, about the work they do in cell-free synthesis, their partnership with Sartorius and the biologics field as a whole.

From Sartorius 30 Mar 2021

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

Caused by SARS-CoV-2, the coronavirus disease 2019 (COVID-19) pandemic continues to spread across the globe.

From Evonik 2 Mar 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Cobra Biologics successfully produced master cell banks for CombiGene’s gene therapy

Cobra Biologics, part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and CombiGene AB, the leading gene therapy company in the Nordic region, today announced that Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.

21 Aug 2020

Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate

Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

From AstraZeneca 17 Jun 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Rentschler Biopharma SE, and Horizon Discovery, a leader in the application of gene editing, today announced the signing of a commercial license agreement.

From Revvity 19 May 2020

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

FDB announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies.

From OXGENE 23 Apr 2020

Wavelength Pharmaceuticals expands supplies of key drug ingredients for critically ill COVID-19 patients

Wavelength Pharmaceuticals, a leading supplier of active pharmaceutical ingredients, today reported that it has greatly expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients.

20 Apr 2020

Cobra Biologics and Karolinska Institutet join forces to develop DNA vaccine against COVID-19

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet, one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.

31 Mar 2020

New partnership enables launch of POCare cell therapy platform within HYGEIA Group’s hospital network

Orgenesis Inc., a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers for therapeutic treatments, today announces a strategic partnership agreement between the HYGEIA Group and the Theracell–Orgenesis joint venture.

9 Dec 2019

Yposkesi chairman to speak on ‘Manufacturing and the CDMO Perspective’ at Cell and Gene Meeting

Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announces that its chairman Frederic Revah Ph.D. will participate as a panelist on the topic of ‘Manufacturing and the CDMO Perspective’.

23 Apr 2019

Cobra Biologics announces appointment of Dr Darrell Sleep as Director of Innovation

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, today announced the appointment of Dr Darrell Sleep as Director of Innovation.

From Charles River 16 Jan 2019

Cobra Biologics to investigate continuous manufacturing of AAV for gene therapies

Cobra Biologics, an international contract development and manufacturing organization with a focus on advanced therapy medicinal products has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.

28 Nov 2018

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

Celltrion and Emory University sign 'Incubation' agreement to develop new drug candidates for atherosclerosis

Celltrion, Inc. signed an 'Incubation' agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

20 Sep 2018

Ology Bioservices wins $8.4 million worth agreement to manufacture anti-Ebola monoclonal antibody

Ology Bioservices, Inc., a biologics contract development and manufacturing organization, announced today that it was awarded an Other Transaction Agreement to support the Joint Project Manager Medical Countermeasure Systems, a component of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for advanced biologics manufacturing services—specifically, to manufacture an anti-Ebola monoclonal antibody.

17 Aug 2018

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Minakem, the CDMO division of Minafin, specialized in custom development and manufacturing of building blocks, GMP intermediates and Active Pharmaceutical Ingredients, today announces it is in the final qualification run to open a new closed-controlled environment high containment production facility in August.

22 Jun 2018

Vetter's new campaign aims to examine applicability of digital trends to injection systems

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

13 Jun 2018

CDMO News and Research

SwiftScale Biologics: Cell-Free Synthesis of Biologics

Evonik partners with BioNTech to manufacture lipids for COVID-19 vaccine

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Cobra Biologics successfully produced master cell banks for CombiGene’s gene therapy

Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

Wavelength Pharmaceuticals expands supplies of key drug ingredients for critically ill COVID-19 patients

Cobra Biologics and Karolinska Institutet join forces to develop DNA vaccine against COVID-19

New partnership enables launch of POCare cell therapy platform within HYGEIA Group’s hospital network

Yposkesi chairman to speak on ‘Manufacturing and the CDMO Perspective’ at Cell and Gene Meeting

Cobra Biologics announces appointment of Dr Darrell Sleep as Director of Innovation

Cobra Biologics to investigate continuous manufacturing of AAV for gene therapies

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Celltrion and Emory University sign 'Incubation' agreement to develop new drug candidates for atherosclerosis

Ology Bioservices wins $8.4 million worth agreement to manufacture anti-Ebola monoclonal antibody

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Vetter's new campaign aims to examine applicability of digital trends to injection systems

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News